The stock of the pharmaceutical company was trading at its lowest level since December 2020. In the past three months, it has declined 27 per cent, as compared to 2 per cent fall in the S&P BSE Sensex. Further, in the past six months, the stock has slipped 37 per cent, as against 3 per cent rise in the benchmark index.
"Laurus is enhancing its capabilities/capacities for the CDMO business from pharma, bio-synthesis, animal health as well as agro-chemicals, which is not only enabling more business from its existing customers but also expanding its customer base. It is also growing its capacity for Non-ARV API and building a product pipeline in the Non-ARV FDF segment. Some of the levers would start contributing meaningfully from FY25 onwards," Motilal Oswal Financial Services said in result update.
However, it has cut its earnings estimate by 4 per cent/11 per cent/6.7 per cent for FY23/FY24/FY25, respectively, considering moderation of CDMO business for FY24 on a high base of FY23, gradual ramp up in Non-ARV FDF, and operational cost related to expanded facilities
Laurus has multiple planned capacity expansions in portfolio based on complexity and scale towards strengthening and diversifying business by an increased focus on non-ARV APIs and formulations and high-growth Custom synthesis segments.
Meanwhile, for October-December quarter (Q3FY23), Laurus Labs delivered operationally in-line performance, led by healthy traction in CDMO-Synthesis/Non-ARV API segment. The growth is also supported by anticipated recovery in ARV FDF segment, which is likely to continue despite pricing challenges, the management said.
The company’s revenues grew 50.2 per cent year-on-year (YoY) to Rs 1,545 crore in Q3FY23 on the back of 210 per cent YoY growth in Custom synthesis to Rs 642 crore led by solid demand from new and existing clients. Formulations de-grew 33 per cent YoY to Rs 249 crore. APIs revenues increased 49.1 per cent YoY to Rs 632 crore driven by increased volumes.
The company’s profit after tax grew 32 per cent YoY to Rs 203 crore for the quarter. Earnings before interest, tax, depreciation, and amortisation (Ebitda) margins declined 161 bps YoY to 26.1 per cent. However, the company maintained its guidance of Rs 6,500 crore revenue and stable Ebitda margins at 28 per cent for FY23.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app